Mira Pharmaceuticals Inc (MIRA)

$1.35 +0.01 (0.75%)
Market Cap 25.74M
Revenue (ttm) 0.00
Net Income (ttm) -7.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 241,900
Avg Vol 520,132
Day's Range N/A - N/A
Shares Out 19.07M
Stochastic %K 70%
Beta 1.69
Analysts Sell
Price Target $14.38

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic st...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786-432-9792
Address:
1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
intratio
intratio Oct. 4 at 3:46 PM
https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.
1 · Reply
Mquigley
Mquigley Oct. 4 at 1:56 PM
$MIRA Friday’s trend lines.
0 · Reply
GSmith3000
GSmith3000 Oct. 4 at 1:05 AM
$MIRA another purchase total of 3.5 million bought by the CEO! 10/1
1 · Reply
Moobumples
Moobumples Oct. 4 at 12:22 AM
$MIRA There was just an insider acquisition of 22,378 shares of Mira Pharmaceuticals Also huge moves with stock allocation currently happening as we speak. Something might be cooking behind the scenes.
1 · Reply
Mquigley
Mquigley Oct. 3 at 10:53 PM
$MIRA The way the 4hr ended today dictates the daily staying below flatline and indicates a 3rd week line on the weekly below flatline Monday at the open. Daily at -10.88 now.
1 · Reply
Mquigley
Mquigley Oct. 3 at 11:49 AM
$MIRA This morning’s trend lines.This current wave has now reached to the 30 minute time frame lower trend line and now has the hourly center trend line price. The lower trend line for the hourly is 1.07 if a bearish wave occurs strong enough to lower the TTM technicals with enough strength. The top trend line bullish with strength reaches 1.47
0 · Reply
Goldwave9
Goldwave9 Oct. 3 at 2:00 AM
$MIRA If this dips to 1.24, I'm in for 2.05 target
0 · Reply
retirementsoon2
retirementsoon2 Oct. 2 at 3:20 PM
$MIRA
0 · Reply
kayo8
kayo8 Oct. 1 at 8:56 PM
$MIRA yall need to relax, look how low the volume is. They will run it down however low they want. Just keep DCA imo and wake up to a random 200% move one day with sustained momentum
1 · Reply
ALEUTVIKING
ALEUTVIKING Oct. 1 at 4:10 PM
$MIRA wtf 😂 my only red
1 · Reply
Latest News on MIRA
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 30, 2025, 7:30 AM EDT - 4 days ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 22, 2025, 8:00 AM EDT - 12 days ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 16, 2025, 7:30 AM EDT - 18 days ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Sep 12, 2025, 7:30 AM EDT - 22 days ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 19, 2025, 8:30 AM EDT - 6 weeks ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Aug 12, 2025, 8:30 AM EDT - 7 weeks ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 30, 2025, 7:30 AM EDT - 2 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 29, 2025, 7:30 AM EDT - 2 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 11, 2025, 8:00 AM EDT - 3 months ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jul 3, 2025, 8:00 AM EDT - 3 months ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 30, 2025, 8:00 AM EDT - 3 months ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 25, 2025, 8:00 AM EDT - 3 months ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 18, 2025, 8:30 AM EDT - 3 months ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025, 8:30 AM EDT - 4 months ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025, 8:00 AM EDT - 5 months ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6, 2025, 8:00 AM EDT - 5 months ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 23, 2025, 8:00 AM EDT - 5 months ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025, 8:00 AM EDT - 6 months ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Apr 1, 2025, 8:00 AM EDT - 6 months ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 24, 2025, 7:30 AM EDT - 6 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 13, 2025, 8:00 AM EDT - 7 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025, 8:00 AM EST - 7 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024, 9:00 AM EST - 10 months ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024, 8:30 AM EST - 10 months ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Nov 20, 2024, 7:44 AM EST - 11 months ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 28, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Oct 21, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 27, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 18, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Sep 11, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 26, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 19, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Aug 12, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 25, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Jul 22, 2024, 2:33 PM EDT - 1 year ago

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 22, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Jun 24, 2024, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Announces Positive Test Results

Jun 17, 2024, 2:07 PM EDT - 1 year ago

MIRA Announces Positive Test Results

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 29, 2024, 8:45 AM EDT - 1 year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 21, 2024, 8:45 AM EDT - 1 year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

May 20, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Mar 21, 2024, 11:04 AM EDT - 1 year ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

MIRA Pharmaceuticals Provides Corporate Update

Feb 5, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Provides Corporate Update

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Dec 4, 2023, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Nov 29, 2023, 8:00 AM EST - 2 years ago

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

Nov 21, 2023, 10:42 AM EST - 2 years ago

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

Nov 21, 2023, 10:09 AM EST - 2 years ago

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

intratio
intratio Oct. 4 at 3:46 PM
https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.https://www.intratio.com/stock-forecast/MIRA Signal update $MIRA: System identifies bearish configuration. ST=-5.1% | MT=-15.7%. Multiple negative catalysts creating downward spiral.
1 · Reply
Mquigley
Mquigley Oct. 4 at 1:56 PM
$MIRA Friday’s trend lines.
0 · Reply
GSmith3000
GSmith3000 Oct. 4 at 1:05 AM
$MIRA another purchase total of 3.5 million bought by the CEO! 10/1
1 · Reply
Moobumples
Moobumples Oct. 4 at 12:22 AM
$MIRA There was just an insider acquisition of 22,378 shares of Mira Pharmaceuticals Also huge moves with stock allocation currently happening as we speak. Something might be cooking behind the scenes.
1 · Reply
Mquigley
Mquigley Oct. 3 at 10:53 PM
$MIRA The way the 4hr ended today dictates the daily staying below flatline and indicates a 3rd week line on the weekly below flatline Monday at the open. Daily at -10.88 now.
1 · Reply
Mquigley
Mquigley Oct. 3 at 11:49 AM
$MIRA This morning’s trend lines.This current wave has now reached to the 30 minute time frame lower trend line and now has the hourly center trend line price. The lower trend line for the hourly is 1.07 if a bearish wave occurs strong enough to lower the TTM technicals with enough strength. The top trend line bullish with strength reaches 1.47
0 · Reply
Goldwave9
Goldwave9 Oct. 3 at 2:00 AM
$MIRA If this dips to 1.24, I'm in for 2.05 target
0 · Reply
retirementsoon2
retirementsoon2 Oct. 2 at 3:20 PM
$MIRA
0 · Reply
kayo8
kayo8 Oct. 1 at 8:56 PM
$MIRA yall need to relax, look how low the volume is. They will run it down however low they want. Just keep DCA imo and wake up to a random 200% move one day with sustained momentum
1 · Reply
ALEUTVIKING
ALEUTVIKING Oct. 1 at 4:10 PM
$MIRA wtf 😂 my only red
1 · Reply
Namni60
Namni60 Oct. 1 at 3:55 PM
$MIRA There is absolutely no reason for this stock to be down today! And it should have been up more on the finalizing of the Merger yesterday.
0 · Reply
Mquigley
Mquigley Sep. 30 at 11:15 PM
$MIRA Today’s trend lines 5 & 15 minute charts.
0 · Reply
MREricPirate
MREricPirate Sep. 30 at 11:13 PM
$MIRA The merger closing was a balance sheet + pipeline expansion event, but not enough to move the stock sharply. The Phase 2 initiation PR is the likely trigger for the next big upward move, because it upgrades MIRA’s status in investors’ eyes from “aspiring” to “active clinical trial player.
1 · Reply
ALEUTVIKING
ALEUTVIKING Sep. 30 at 4:29 PM
$MIRA
1 · Reply
Jaespresso
Jaespresso Sep. 30 at 4:04 PM
$MIRA
0 · Reply
retirementsoon2
retirementsoon2 Sep. 30 at 1:58 PM
$MIRA
0 · Reply
lisaparsons
lisaparsons Sep. 30 at 1:39 PM
$MIRA Acquisistion of SKY approved. Why not moving?
4 · Reply
ALEUTVIKING
ALEUTVIKING Sep. 30 at 12:01 PM
$MIRA
0 · Reply
YoloAlfred
YoloAlfred Sep. 30 at 11:59 AM
$MIRA Stressed out Rats
0 · Reply
Stockmarine
Stockmarine Sep. 30 at 11:46 AM
$MIRA does this mean the merger is complete or not yet ?
3 · Reply
Moobumples
Moobumples Sep. 30 at 11:33 AM
$MIRA Big move from $MIRA today 👀 They just closed the acquisition of SKNY Pharmaceuticals and added SKNY-1 to their pipeline — a drug candidate targeting both obesity and nicotine addiction. Preclinical results showed up to 30% weight reduction without muscle loss, plus reduced nicotine and food cravings. That’s huge potential in two massive markets. On top of that, MIRA is still advancing Ketamir-2 (a next-gen ketamine analog for neuropathic pain, depression, PTSD) and MIRA-55 (cannabis-derived, designed to provide pain relief comparable to morphine without addiction risk). This deal also strengthens their balance sheet with $5M in marketable securities. Financially stronger, pipeline bigger, and tackling some of the fastest-growing health challenges out there.
0 · Reply
Abo_Hamza
Abo_Hamza Sep. 30 at 11:32 AM
$MIRA
0 · Reply